Use of antithrombin in extracorporeal membrane oxygenation

• US 9,511,087 B2
• Filed: 08/02/2013
• Issued: 12/06/2016
• Est. Priority Date: 08/03/2012
• Status: Active Grant

• Current Assignee: rEVO Biologics, Inc. (Agence des Participations de l’Etat)
• Original Assignee: rEVO Biologics, Inc. (Agence des Participations de l’Etat)
• Inventors: Frieling, Johan, Lowry, Simon
• Primary Examiner(s): Steele, Amber D
• Application Number:
  US14/239,943
• Publication Number:
  US 20140194360A1
• Time in Patent Office: 1,222 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

In one aspect, the disclosure provides methods of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®.

Claims

1. A method of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation, the method comprising:

administering to a subject having extracorporeal membrane oxygenation a therapeutically effective amount of recombinant antithrombin to suppress blood clotting and/or prevent hemorrhage.

2. The method of claim 1, wherein the antithrombin has a high mannose glycosylation pattern.

3. The method of claim 1, wherein the antithrombin has a high fucose glycosylation pattern.

4. The method of claim 1, wherein the antithrombin comprises GalNac (N-acetylgalactosamine).

5. The method of claim 1, wherein the antithrombin is transgenically produced antithrombin.

6. The method of claim 5, wherein the antithrombin is transgenically produced in a goat.

7. The method of claim 1, wherein the antithrombin is a transgenic human alpha-antithrombin that is produced in a goat mammary gland.

8. The method of claim 1, wherein the antithrombin is administered at a dose of 6 units per kg.

9. The method of claim 1, wherein the antithrombin is administered at a dose of 80 units per kg.

10. The method of claim 1, wherein the antithrombin is administered at a dose of 295 units per kg.

11. The method of claim 1, wherein the antithrombin is administered at a dose sufficient to maintain a level of antithrombin activity present in the blood at the time of initiation of extracorporeal membrane oxygenation.

12. The method of claim 1, wherein the antithrombin is administered in one dose.

13. The method of claim 1, wherein the antithrombin is administered by a bolus followed by continuous infusion.

14. The method of claim 1, further comprising administering heparin.